PharmD Signal

Deep dives, evidence grades, and clinical tools, all in one place.

🧠 Clinical library

Clinical Specialty Index

131 articles indexed across 16 specialties, each reviewed by a licensed pharmacist before publication.

⭐ Featured free samples

Three of our best full deep-analysis reports: hand-picked, free to read in full, no subscription required.

🔓 Free Sample
Nephrology / Renal Pharmacy ConfirmatoryGrade: Moderate

Finerenone Outperforms Spironolactone for Cardiorenal Protection in Moderate CKD

American journal of cardiovascular drugs : drugs, devices, and other interventions · Jul 20, 2026

Finerenone emerges as the safer choice for CKD patients.

Read Free →
🔓 Free Sample
Neurology / Neuropharmacology ConfirmatoryGrade: Low

Tenecteplase Shortens Stroke Treatment and Transfer Times

JAMA network open · Jul 13, 2026

Tenecteplase speeds up stroke thrombolysis compared to alteplase.

Read Free →
🔓 Free Sample
Rheumatology / Immunology ConfirmatoryGrade: Moderate

EULAR 2025 Streamlines Rheumatoid Arthritis DMARD Management to Nine Recommendations

Annals of the rheumatic diseases · Jun 13, 2026

New EULAR guidelines redefine RA management with DMARDs.

Read Free →
Showing 1 from 1 topic.Sort: Newest | Oldest
2025 AHA/ACC Multi-Society Hypertension Guideline Redefines Risk and Treatment Thresholds
Hypertension Practice-changing Grade: Moderate
Writing Committee Members*, Jones DW, Ferdinand KC, et al.
📅 Oct 1, 2025 · Hypertension

The 2025 AHA/ACC Guideline introduces PREVENT-based CVD risk, new secondary hypertension triggers, and major changes in initial drug therapy for pharmacists managing hypertension.